Ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure

Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, briefly discusses his talk at the 1st Annual MPN Workshop of the Carolinas, which focused on ruxolitinib for treating myeloproliferative neoplasms (MPNs). Although the agent changed the therapeutic landscape for patients with these malignancies, treatment-related adverse events, namely cytopenias, limit the doses that can be prescribed and subsequently affect the efficacy of the treatment. Additionally, patients who fail on ruxolitinib have a poor prognosis. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.